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Reperfusion Strategies in Acute
ST-Segment Elevation Myocardial Infarction
A Comprehensive Review of Contemporary Management Options
William E. Boden, MD, FACC,* Kim Eagle, MD, FACC,† Christopher B. Granger, MD, FACC‡
Buffalo, New York; Ann Arbor, Michigan; and Durham, North Carolina
There are an estimated 500,000 ST-segment elevation myocardial infarction (STEMI) events in the U.S. annually.
Despite improvements in care, up to one-third of patients presenting with STEMI within 12 h of symptom onset
still receive no reperfusion therapy acutely. Clinical studies indicate that speed of reperfusion after infarct onset
may be more important than whether pharmacologic or mechanical intervention is used. Primary percutaneous
coronary intervention (PCI), when performed rapidly at high-volume centers, generally has superior efficacy to
fibrinolysis, although fibrinolysis may be more suitable for many patients as an initial reperfusion strategy. Be-
cause up to 70% of STEMI patients present to hospitals without on-site PCI facilities, and prolonged door-to-
balloon times due to inevitable transport delays commonly limit the benefit of PCI, the continued role and impor-
tance of the prompt, early use of fibrinolytic therapy may be underappreciated. Logistical complexities such as
triage or transportation delays must be considered when a reperfusion strategy is selected, because prompt fi-
brinolysis may achieve greater benefit, especially if the fibrinolytic-to-PCI time delay associated with transfer ex-
ceeds 1 h. Selection of a fibrinolytic requires consideration of several factors, including ease of dosing and
combination with adjunctive therapies. Careful attention to these variables is critical to ensuring safe and rapid
reperfusion, particularly in the prehospital setting. The emerging modality of pharmacoinvasive therapy, al-
though controversial, seeks to combine the benefits of mechanical and pharmacologic reperfusion. Results from
ongoing clinical trials will provide guidance regarding the utility of this strategy. (J Am Coll Cardiol 2007;50:
917–29) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.084r
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the estimated annual incidence of new and recurrent
yocardial infarction (MI) in the U.S. is 865,000 events (1),
ith ST-segment elevation myocardial infarction (STEMI)
omprising an estimated 500,000 events per year (2). Mor-
ality in patients with STEMI has declined substantially in
eveloped countries over the past 20 years (3). However, up
o one-third of eligible patients with STEMI still receive no
rom the *School of Medicine and Biomedical Sciences, State University of New
ork, and Kaleida Health System, Buffalo, New York; †University of Michigan
ardiovascular Center, Ann Arbor, Michigan; and the ‡Division of Cardiology,
uke University Medical Center, Durham, North Carolina. Supported by PDL
ioPharma, Inc. Dr. Boden has received research grants from Kos/Abbott, Sanofi-
ventis, Pfizer, and Merck, has received honoraria from Sanofi-Aventis, Bristol-
yers Squibb, CVT, Kos/Abbott, Pfizer, Merck, and PDL BioPharma, and has been
consultant for Kos/Abbott and PDL BioPharma. Dr. Eagle has received grant and
esearch support from Biosite, Bristol-Myers Squibb, Cardiac Sciences, Blue Cross/
lue Shield of Michigan, the Hewlett Foundation, the Mardigian Fund, Pfizer,
anofi-Aventis, and the Varbedian Fund and has been a consultant for the National
nstitutes of Health National Heart, Lung, and Blood Institute, Pfizer, Sanofi-
ventis, and the Robert Wood Johnson Foundation. Dr. Granger has received
esearch funding from AstraZeneca, Procter & Gamble, Sanofi-Aventis, Alexion,
ovartis, Boehringer-Ingelheim, Genentech, Berlex, GlaxoSmithKline, Bristol-
yers Squibb, and The Medicines Company and has been a consultant for
straZeneca, Sanofi-Aventis, GlaxoSmithKline, and The Medicines Company.o
Manuscript received February 6, 2007; revised manuscript received April 25, 2007,
ccepted April 30, 2007.eperfusion therapy acutely (4,5). Timely reperfusion of the
nfarct-related coronary artery using fibrinolysis or percuta-
eous coronary intervention (PCI) is central to optimal
TEMI treatment (3,6), reducing infarct size, minimizing
yocardial damage, preserving left ventricular function, and
ecreasing morbidity and mortality (7). However, the prin-
ipal objective of prompt reperfusion has become overshad-
wed by debate over which approach (mechanical or phar-
acologic) is superior. The more compelling question is
ow optimal reperfusion can best be achieved in STEMI,
indful of the fact that 60% to 70% of STEMI patients
resent initially to hospitals without ready access to primary
CI. Data from the National Registry of Myocardial
nfarction (NRMI)-3 and -4 registries highlight how few
TEMI patients (only 4%) who are transferred for primary
CI achieve door-to-balloon times of 90 min (8), which
epresents the American College of Cardiology (ACC)/
merican Heart Association (AHA) standard of care
enchmark (2).
The goal of this paper is to highlight reperfusion options
n STEMI, with regard to efficacy and safety, as well as
emporal and logistic factors that may affect treatment
utcomes and thus clinical decision making.
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Reperfusion Strategies in Acute STEMI September 4, 2007:917–29Utilization of
Reperfusion Therapy
As previously noted, reperfusion
therapy is underutilized in pa-
tients with STEMI. In analyses
of data from the NRMI-2 data-
base (4), and the GRACE (Global
Registry of Acute Coronary Events)
study (5), factors associated with
eligible patients not receiving
reperfusion therapy included age
75 years, female gender, pre-
sentation without chest pain, and
a history of cardiovascular dis-
ease. In addition, the EDQMI
(Emergency Department Quality
in Myocardial Infarction) study
found that failure to identify high-
risk electrocardiogram (ECG)
findings in patients with acute MI
was associated with greater odds
of ideal candidates not receiving
eperfusion therapy (9). The ECG findings are key in
aking prompt STEMI treatment decisions, identifying
atients with ST-segment elevation who may benefit from
eperfusion therapy and patients with increased mortality
isk, such as those with left bundle branch block.
The 2004 ACC/AHA guidelines for the management of
atients with STEMI recommend that an experienced
mergency department (ED) physician should evaluate a
2-lead ECG within 10 min of arrival in the ED for all
atients with chest discomfort or other symptoms suggestive
f STEMI. If the initial ECG is not diagnostic of STEMI,
ut the patient continues to experience symptoms and there
s a high clinical suspicion of STEMI, the guidelines
ecommend performing serial ECGs every 5 to 10 min or
ontinuous 12-lead ST-segment monitoring to detect de-
elopment of ST-segment elevation, which may in turn
nsure use of reperfusion therapy in eligible patients. Where
vailable, chest pain centers with established protocols can
erform any necessary ongoing monitoring of patients to
void both inappropriate discharge from the ED due to a
issed diagnosis and unnecessary hospitalizations (10).
ercutaneous Coronary Intervention
he ACC/AHA STEMI guidelines recommend PCI as
he initial approach to management of STEMI, contingent
pon treatment at centers with a skilled PCI laboratory and
apid initiation (within 90 min of first medical contact) (2).
his is based on multiple randomized clinical trials dem-
nstrating superiority of rapid primary PCI over fibrinolysis
n STEMI (11–16). However, for many patients these
riteria for primary PCI to be preferred will not be met, and
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
ECG  electrocardiogram
ED  emergency
department
EMS  emergency medical
services
MI  myocardial infarction
NRMI  National Registry
of Myocardial Infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctiont is important to note that the ACC/AHA guidelines also ttate that there is no strong preference between PCI and
brinolysis as the choice of initial reperfusion therapy in
atients who present within 3 h after symptom onset (2).
his is based, in part, on the CAPTIM (Comparison of
ngioplasty and Prehospital Thrombolysis in Acute Myo-
ardial Infarction) and PRAGUE-2 (Primary Angioplasty
n Patients Transported From General Community Hospi-
als to Specialized PTCA Units With or Without Emer-
ency Thrombolysis-2) trials, which suggested that earlier-
resenting patients (within 2 to 3 h) had similar or lower
ortality with fibrinolysis than with primary PCI (17,18).
In the setting within which the ACC/AHA guidelines
ecommend primary PCI, it offers several important poten-
ial advantages over pharmacologic reperfusion: It is suitable
or90% of patients (2), establishes initial Thrombolysis In
yocardial Infarction (TIMI) flow grade 3 in 70% to 90%
f patients (2), nearly eliminates the risk of intracranial
emorrhage, and is preferable to alternative treatments in
igh-risk patients, such as those with cardiogenic shock,
evere congestive heart failure, or hemodynamic or electrical
nstability (2,19).
Appropriately selected patients undergoing primary PCI
ere shown to have lower rates of nonfatal reinfarction,
troke, and short-term mortality than fibrinolytic recipients
n a meta-analysis of data from 23 randomized trials
nrolling fibrinolytic-eligible patients with STEMI (20). It
hould be noted, however, that 24% of patients in the
brinolytic group received the nonfibrin-specific agent
treptokinase, which is rarely used in the U.S. and has been
hown to be less effective than alteplase in reducing mor-
ality in STEMI (21). Based on 5 studies that compared
mergent hospital transfer for primary PCI (with additional
ransfer-related delay averaging 39 min) with on-site fibri-
olysis, PCI was still associated with significantly better
utcomes; however, the difference was mainly driven by less
einfarction in the setting of low rates of rescue and early
ngiography (20). Moreover, the transfer-related delays
rom first-door-to-balloon were much shorter (100 to 120
in) compared with U.S. registry data (180 to 240 min)
8,22). Thus, while these trials show that transfer can be
one rapidly in selected centers with good outcomes in
urope, they have limited direct relevance to current U.S.
ractice.
enefits of Early Reperfusion:
he Early-Open-Artery Theory
he early-open-artery theory suggests that benefits of reper-
usion in patients with STEMI are directly related to the
peed and completeness with which patency of the infarct-
elated coronary artery is re-established. Mortality has been
hown to be lower among patients in whom TIMI flow
rade 2 to 3, compared with TIMI flow grade 0 to 1, was
chieved within 90 min after acute MI (23).
This is strongly supported by clinical studies confirming
he important relationship between achieving prompt ante-
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September 4, 2007:917–29 Reperfusion Strategies in Acute STEMIrade coronary flow of the infarct artery and improved
linical outcomes, for both primary PCI (22,24–27) and
brinolysis (21,28,29). An analysis by Boersma et al. indi-
ated that the 35-day mortality benefit associated with early
reatment equated to 1.6 lives per 1,000 patients per hour of
elay from symptom onset to treatment, with even more of
n impact of time in the early hours (Fig. 1) (28). However,
he recent Occluded Artery Trial showed that PCI provided
o delayed benefit over optimal medical therapy alone in
table patients with persistent total occlusion of the infarct-
elated coronary artery 3 to 28 days after acute MI who met
riteria for high risk (30), indicating that there is no
ndication to open an occluded vessel outside the therapeu-
ic window in an asymptomatic patient following STEMI.
CC/AHA Guidelines for
electing a Reperfusion Strategy
he 2004 ACC/AHA guidelines provide recommendations
n selecting a reperfusion strategy for patients with STEMI
Fig. 2). The first step is to determine time from onset of
ymptoms, the presence of high-risk attributes, the relative
isks associated with fibrinolysis, and estimated total time
equired for achieving PCI balloon inflation; these factors
ogically determine treatment selection. An invasive strategy
s generally preferred if first door-to-balloon time can be
ealistically achieved within 90 min if there is high risk from
TEMI or fibrinolysis is contraindicated (2). The first of
hese criteria sets an important benchmark, and it should be
oted that the goal of performing primary PCI within 90
in of first medical contact represents the longest time that
hould be considered acceptable rather than the ideal time
rame (31). Yet registry data have shown that a door-to-
Figure 1 Absolute 35-Day Mortality
Versus Fibrinolytic Treatment Delay*
*Solid circles  information from trials included in Fibrinolytic Therapy Trial-
ists’ Collaborative Group analysis; open circles  information from additional
trials; small squares  data beyond scale of x/y cross. The linear and nonlin-
ear regression lines are fitted within these data, weighted by inverse of the
variance of the absolute benefit in each datapoint. Solid squares  average
effects in 6 time-to-treatment groups (areas of squares inversely proportional
to variance of absolute benefit described). Reproduced with permission from
Boersma et al. (28).aalloon time of 90 min is not achieved in the majority of
atients undergoing primary PCI, particularly if transfer is
equired (8,32). These data suggest that many STEMI
atients are being denied the optimal treatment for prompt
eperfusion.
Fibrinolysis is preferred if 3 h have elapsed from
ymptom onset, there is an anticipated delay that decreases
he potential advantage of PCI, or an invasive strategy is not
n option (e.g., owing to vascular access difficulties or lack of
ccess to a skilled PCI laboratory with skilled operators) (2).
hus, within 3 h of symptom onset, in the absence of delays
o initiating an invasive strategy, the ACC/AHA guidelines
ndicate that there is no preference for either PCI or
brinolysis (2), although if primary PCI can be performed
apidly, it is generally preferred in the U.S. owing to safety
nd cost-effectiveness (i.e., shorter length of stay) (33,34). A
ecent pooled analysis suggested a consistent advantage of
rimary PCI over fibrinolysis regardless of time from
ymptom onset to presentation (35). However, Gersh and
ntman (36) have commented that this conclusion is
ontroversial, and cautioned that analyses such as this
hould not be used as justification for exclusively choosing a
trategy of primary PCI without taking into account a
ealistic estimate of the time needed to implement this
trategy in all clinical settings.
Regardless of the reperfusion strategy, the guidelines
ecommend treatment with unfractionated or low-
olecular-weight heparin (2). The EXTRACT (Enoxapa-
in and Thrombolysis Reperfusion for Acute Myocardial
nfarction Treatment)–TIMI-25 (37) and CLARITY
Clopidogrel as Adjunctive Reperfusion Therapy)–
IMI-28 (38) studies indicated that low-molecular-weight
eparins provided improved clinical outcomes over unfrac-
ionated heparin. Treatment with enoxaparin in the first of
hese studies (37) was associated with modestly increased
leeding compared with unfractionated heparin, although
he rate of the composite end point of death, nonfatal
einfarction, and nonfatal major bleeding was lower with
noxaparin (37). In the OASIS-6 (Organization for the
ssessment of Strategies for Ischemic Syndromes-6) study,
he factor Xa inhibitor fondaparinux also improved out-
omes versus usual care (unfractionated heparin or placebo if
eparin was not indicated), although this was seen in
atients who received fibrinolysis or no reperfusion therapy
ut not with primary PCI (39).
ractical Limitations of Primary
CI as a Universal Reperfusion Strategy
rimary PCI would likely become the universal “dominant
efault strategy” for prompt early reperfusion if resource and
ogistical constraints did not limit its more broad-based
doption. As discussed previously, time to reperfusion is the
ost critical variable in STEMI management and is partic-
larly important for PCI. Availability of invasive facilities is
nother important determinant of the feasibility of PCI. It
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Reperfusion Strategies in Acute STEMI September 4, 2007:917–29as been estimated that25% of acute-care hospitals in the
.S. have PCI programs (8); unless rapid transfer to an
ppropriately staffed facility is available and systems are in
lace to make it possible, PCI generally involves unaccept-
ble delays. Door-to-balloon times of90 min are achieved
n only approximately one-third of patients who do not
equire transfer (32) and in a much smaller proportion of
atients presenting to hospitals without ready access to
rimary PCI. Real-world data from the NRMI-3 and -4
atabases (n  4,278) showed that total door-to-balloon
imes of90 and120 min were achieved in only 4.2% and
6.2%, respectively, of STEMI patients transferred for PCI
median 180 min) (Fig. 3) (8).
Because an estimated 80% of the U.S. population lives
ithin 60 min of a PCI hospital (40), programs are being
eveloped and evaluated nationwide which involve direct
mergency medical services (EMS) delivery to the nearest
rimary PCI center and rapid transfer systems (41). How-
ver, at present few such programs are operational. The
mergency medical transportation systems that are currently
n place are likely to remain in place for the foreseeable
uture and are not conducive to making primary PCI a
ealistic alternative for most of the U.S. population. Addi-
ional barriers to the rapid transport of patients with
Figure 2 American College of Cardiology/American Heart Asso
*Operator experience 75 primary PCI cases per year. †Team experience 36 pr
that the estimated delay to the implementation of the invasive strategy is 1
Reprinted with permission from Antman et al. (2). ICH  intracerebral hemorrh
myocardial infarction.TEMI to primary PCI facilities include a minority ofMS systems having 12-lead ECG capabilities; a minority
f patients with chest pain transported by EMS having
TEMI; mandates to transport patients to the nearest
acility, even when the facility is not primary PCI capable
nd fibrinolysis is contraindicated; and long transport
n Guidelines for Selecting a Reperfusion Strategy
PCI cases per year. ‡Applies to fibrin-specific agents. §This calculation implies
us initiation of fibrinolytic therapy immediately with a fibrin-specific agent.
CI  percutaneous coronary intervention; STEMI  ST-segment elevation
Figure 3 Door-to-Balloon Time for Patients Transferred
for Primary Percutaneous Coronary Intervention
Reprinted with permission from Nallamothu et al. (8).ciatio
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September 4, 2007:917–29 Reperfusion Strategies in Acute STEMIimes in both metropolitan and rural areas (31). In
ddition, when a patient is initially brought to a non–
CI-capable facility and is considered appropriate for
rimary PCI, they may have to wait for the next available
mbulance for transport (31).
Rapid mobilization of the multidisciplinary catheter-
zation team is a critical time-dependent variable specific
o primary PCI, especially during routine “off-shift” night
nd weekend hours. In an analysis of NRMI-3 and -4
ata, the factors associated with delayed treatment in-
luded hospital presentation during off-hours (Table 1)
8). Another analysis of NRMI-3 and -4 data found that
resentation during off-hours prolonged door-to-balloon
imes by 21.3 min (p  0.001) and reduced the proportion
f patients undergoing primary PCI within the ACC/AHA
uideline-recommended time frame (Fig. 4A) (42). The
ncrease in door-to-needle time during off-hours, although
tatistically significant, was only 1 minute (p  0.001).
lmost all of the observed delay for PCI during off-hours
as attributed to additional time between ECG completion
nd arrival in the catheterization laboratory (20.8 min; p 
.001) (Fig. 4B). Adjusted in-hospital mortality for patients
resenting during off-hours was significantly higher than for
atients admitted during regular hours (p  0.02); this
ifference was no longer significant after adjustment for
eperfusion treatment time. Thus, time of day and day of
eek, as well as the institutional ability to activate the
Characteristics Associated With TotalDoo -to-Balloon Time Aft r Multivariate Adjustm
Table 1 Characteristics Associated With ToDoor-to-Balloon Time After Multivar
Characteristic
Diabetes mellitus
Prior coronary artery bypass graft
No chest pain at presentation
Primary ECG findings
Left bundle branch block
2 leads with ST-segment elevation
3 or 4 leads with ST-segment elevation
5 leads with ST-segment elevation
Symptoms before arrival
2 h
2–6 h
6–12 h
Time and day of arrival
Weekday between 12 AM and 7:59 AM*
Weekend between 12 AM and 7:59 AM*
Facility type
Urban and nonteaching
Urban and teaching
Rural and nonteaching
Rural and teaching
Percentage of reperfusion therapy patients receiving PCI
20
20–90
90*Compared with weekday arrival between 4 PM and 12 AM. Reprinted with pe
CI  confidence interval; ECG  electrocardiogram; PCI  percutaneous cardiac catheterization laboratory in an expedient manner,
ust be considered when a reperfusion strategy is selected.
Another study using NRMI-3 and -4 data highlighted
he importance of door-to-balloon times in STEMI. In
atients with STEMI (n  29,222) who underwent PCI
ithin 6 h of presentation, longer door-to-balloon times
ere associated with higher in-hospital mortality (3.0%,
.2%, 5.7%, and 7.4% for door-to-balloon times of 90, 91
o 120, 121 to 150, and 150 min, respectively; p  0.01);
his was seen within each of the subgroups of patients with
ymptom onset-to-door times of 1 h, 1 to 2 h, or 2 h
43). Although this type of analysis may be confounded
ecause delays are also more common in sicker patients, it
upports the overwhelming data showing the relationship of
ime to reperfusion and outcome. Other studies suggest that
elay to primary PCI is especially important in earlier
resenting patients (24).
The findings of these studies underscore the importance
f realistically assessing transfer and catheterization labora-
ory activation times before selecting a reperfusion strategy,
nd implementing organizational strategies to reduce door-
o-balloon time for patients transferred for primary PCI.
enry et al. reported that implementation of a standardized
rotocol and integrated transfer system significantly reduced
oor-to-balloon times (44). Several studies have shown a
elationship between obtaining prehospital ECGs and more
apid treatment with both fibrinolytic therapy and primary
djustment
Door-to-Balloon Time, min (95% CI) p Value
8.2 (2.5 to 14.0) 0.004
17.4 (7.0 to 28.0) 0.001
17.9 (7.0 to 29.1) 0.001
— 0.001
8.3 (21.5 to 5.7)
31.7 (42.5 to20.5)
43.8 (54.6 to32.5)
— 0.001
13.5 (7.5 to 19.7)
30.4 (20.7 to 40.4)
12.9 (5.4 to 20.8) 0.001
16.2 (5.3 to 27.4) 0.003
— 0.001
23.9 (12.6 to 35.6)
28.0 (4.4 to 53.2)
73.0 (30.6 to 121.2)
21.2 (5.9 to 50.5)
— 0.16
7.3 (19.8 to 5.9)ent
tal
iate Armission from Nallamothu et al. (8).
oronary intervention.
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Reperfusion Strategies in Acute STEMI September 4, 2007:917–29CI (45–47). As a consequence, the coordinating commit-
ee of the National Heart, Lung, and Blood Institute’s
ational Heart Attack Alert Program called for implemen-
ation of prehospital 12-lead ECG programs by EMS
ystems providing advanced life support, to identify patients
ith STEMI before arrival at the ED and thus facilitate
ore rapid treatment (48). It has also been suggested that a
ational policy for the treatment of patients with STEMI
hould be adopted in the U.S., to develop a coordinated
ystem of care, modeled after the Level I Trauma System,
ithin which patients with STEMI are transported directly
o designated centers (49). However, this issue remains
ontroversial; in a recent paper, Rathore et al. (50) cautioned
hat the expected benefits of “regionalization” of STEMI
are may not be fully realized, and suggested that more
ompelling evidence of potential benefits and greater un-
erstanding of potential consequences are needed before
Figure 4 Influence of Patient Arrival Period on Time to Treatme
Regular hours include weekdays, 7 AM to 5 PM. Off hours include weekdays, 5 PM to
cutaneous coronary intervention (PCI) by patient arrival period. The American Colle
times be 30 min and door-to-balloon time 90 min. (B) Door-to-drug and door-to
electrocardiogram (ECG) completion. Data to drug is time from ECG completion to
to arrival at catheterization laboratory. Catheter lab to balloon is time from arrival
Magid et al. (42).uch a policy could be feasibly implemented nationally. lClinical outcomes following PCI have been shown to be
nfluenced by the institutional volume of primary PCI
erformed, with significantly better outcomes achieved in
igher-volume centers (25,51). The ACC/AHA STEMI
uidelines specify that one of the criteria for an invasive
eperfusion strategy to be preferred is availability of a skilled
CI laboratory (operator and team experience of 75 and
36 primary PCI cases per year, respectively) (2). The
uidelines include availability of surgical backup as another
riterion for preferring an invasive strategy (2). However, a
eport from the ACC National Cardiovascular Data Reg-
stry indicates that PCI is increasingly being performed at
acilities without on-site surgical backup (52), and it has
een suggested that such a recommendation may be unwar-
anted, based on recent data from the Swedish Coronary
ngiography and Angioplasty Registry (53).
Overall, in the appropriate clinical, temporal, and
and all weekend times. (A) Guideline adherence for fibrinolytic therapy and per-
ardiology/American Heart Association guidelines recommend that door-to-drug
n subintervals by patient arrival. Door to data is time from hospital arrival to
istration of fibrinolytic therapy. Data to catheter lab is time from ECG completion
iac catheterization laboratory to balloon inflation. Reprinted with permission fromnt
7 AM,
ge of C
-balloo
admin
at cardogistical setting, PCI has greatly advanced the care of
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September 4, 2007:917–29 Reperfusion Strategies in Acute STEMITEMI patients. However, when the criteria required for
ptimal benefit of PCI cannot realistically be achieved, as
s the case for many patients, pharmacologic reperfusion
hould not be delayed. When necessary, rescue PCI
emains an important option after fibrinolytic therapy,
ith studies showing that appropriate use of rescue PCI
mproves outcomes compared with conservative therapy
54,55), with a similar risk of major bleeding complica-
ions to that seen with primary PCI (56).
ole of Fibrinolysis
he practical limitations of primary PCI that limit its
ecoming the universal “dominant default strategy” for
rompt reperfusion inevitably lead to a strategy of early
brinolysis as having a more prominent role. Results from
any studies have demonstrated time dependence of the
enefit of PCI versus fibrinolysis (17,18,57). An analysis of
1 trials showed that as PCI-related time delay increased,
bsolute mortality reduction at 4 to 6 weeks favoring
rimary PCI versus fibrinolysis decreased (0.94% decrease
er additional 10-min delay; p  0.006) (Fig. 5), with
pparent equivalence after a PCI-related time delay of 62
in (57). This is reflected by the ACC/AHA STEMI
uidelines, which indicate that fibrinolysis is generally
referred when there is a delay to implementing an
nvasive strategy such that door-to-balloon time minus
oor-to-needle time exceeds 1 h. Thus, where PCI
annot be performed within the optimal time frame,
brinolysis can provide rapid reperfusion. Prehospital
brinolysis offers the best potential to improve outcomes
or patients with STEMI in the U.S. by providing even
ore rapid reperfusion.
Figure 5 Absolute RR in 4- to 6-Week Mortality Rates With
Primary PCI as a Function of PCI-Related Time Delay
Circle size reflects the sample size of the individual study. The solid line repre-
sents the weighted meta-regression. Values 0 favor PCI and values 0 favor
fibrinolysis. PCI  percutaneous coronary intervention; RR  risk reduction.
Reprinted with permission from Nallamothu et al. (57).trehospital Fibrinolysis
number of studies have demonstrated that prehospital
brinolytic administration can significantly decrease time
rom symptom onset to treatment (58–61). Patients receiv-
ng prehospital fibrinolysis achieved resolution of ST-
egment elevation earlier than historical controls, indicating
decrease in time to reperfusion (60). This is reflected by
everal studies showing improved outcomes, such as mor-
ality (Fig. 6), with prehospital fibrinolysis (59,61,62).
In a large meta-analysis, mortality was significantly lower
mong patients receiving prehospital versus inhospital fibri-
olysis (odds ratio 0.83; 95% confidence interval 0.70 to
.98) (61). Early administration of prehospital fibrinolysis is
articularly beneficial (58,62). Comparison of prehospital
brinolysis with transfer to a hospital for immediate PCI in
he CAPTIM trial revealed no statistically significant
etween-treatment difference regarding the composite pri-
ary end point (death, nonfatal reinfarction, and nonfatal
isabling stroke within 30 days) or mortality, suggesting
hat PCI did not confer an event-free survival advantage
63). Among patients randomized 2 h after symptom
nset, there was a strong trend toward lower 30-day
ortality with prehospital fibrinolysis (2.2% vs. 5.7%; p 
.058) (17).
Clinical trials data support the safety and efficacy of
rehospital fibrinolysis in the treatment of STEMI. Based
n the many studies showing the benefit of early initiation
f fibrinolytic therapy, the ACC/AHA STEMI guidelines
tate that “it seems reasonable to expect that if fibrinolytic
herapy could be started at the time of prehospital evalua-
Figure 6 Mortality Benefit With Prehospital
Fibrinolysis Versus Inhospital Fibrinolysis
Diagonal line represents equal rates; above line favors inhospital fibrinolysis
and below line favors prehospital fibrinolysis. Reprinted with permission from
Morrison et al. (61).ion, a greater number of lives could be saved” (2). This
t
a
p
P
i
w
w
o
e
s
c
fi
E
l
o
p
p
a
a
s
p
b
E
T
fi
o
r
S
s
D
o
i
p
w
t
o
e
a
i
b
t
(
b
t
b
t
i
r
t
i
t
s
B
t
a
P
p
r
h
c
w
a
(
p
c
I
T
b
t
4
i
A
w
3
C
*
f
924 Boden et al. JACC Vol. 50, No. 10, 2007
Reperfusion Strategies in Acute STEMI September 4, 2007:917–29reatment is feasible in locations where the fibrinolytic is
dministered by paramedics (under the supervision of a
hysician), general practitioners, or medical intensivists.
rehospital fibrinolysis may also decrease time to treatment
n other settings, including rural or congested urban areas
here transportation times are long, as well as areas in
hich primary PCI facilities are not immediately available
r where time to mobilize the appropriate team may be
xcessive. Unfortunately, while there have been a few
uccessful programs in rural U.S. settings, the U.S. health
are system has not fostered the availability of prehospital
brinolysis. This may relate to generally poor funding of
MS, especially in rural environments, and to concerns over
egal liability, particularly when critical decisions are made
utside of traditional hospital settings. Implementation of
rehospital fibrinolysis will require interest, support, and
articipation from civic and community leaders, hospital
dministrators, cardiologists, and ED physicians; appropri-
te structuring, resourcing and medical direction for EMS
ervices; and resolution of cost issues relating to provision of
rehospital treatment, e.g., through fee-for-service reim-
ursement of EMS agencies for drugs administered by
MS personnel (64).
he choice of a fibrinolytic agent. There are several
brinolytic agents currently approved for the management
f STEMI; key characteristics of these agents are summa-
ized in Table 2 (2,65–76). The fibrinolytics approved for
TEMI appear to differ in a number of ways, such as fibrin
pecificity.
OSING CONSIDERATIONS. The development of bolus and
f nonweight-based dosing as alternatives to intravenous
nfusion regimens with dosing based on body weight has the
otential to simplify fibrinolytic administration (60,63,77),
hich may be especially important in the prehospital set-
ing. The use of bolus fibrinolytic therapy, such as reteplase
r tenecteplase, is appealing to EMS personnel and may
nable treatment to be initiated more quickly than with an
gent administered by infusion (78). Nonweight-based dos-
haracteristics of Fibrinolytics Commonly Used in the Treatment o
Table 2 Characteristics of Fibrinolytics Commonly Used in the
Streptokinase
Dose 1.5 MU over 30–60 min Up
Bolus administration No
Antigenic Yes
Allergic reactions (hypotension most common) Yes
Systemic fibrinogen depletion Marked
TIMI flow grade 3, % 30
TIMI flow grade 2/3, % 55
Rate of intracerebral hemorrhage, % 0.4 
Fibrin specificity 
Fibrin affinity 
Cost per recommended MI dose (U. S.$)‡ 562.50
Bolus 15 mg, infusion 0.75 mg/kg times 30 min (maximum 50 mg), then 0.5 mg/kg not to exc
or 60 to 69 kg, 40 mg for 70 to 79 kg, 45 mg for 80 to 89 kg, and 50 mg for 90 kg or more. ‡Red Boo
MI  myocardial infarction; MU  megaunits; STEMI  ST-elevation myocardial infarction; TIMI  Throng may have the potential to decrease treatment errors,
ecause visual approximation of a patient’s weight is subject
o substantial errors (79–83). In the ASSENT-3 PLUS
Assessment of the Safety and Efficacy of a New Throm-
olytic Regimen-3 Plus) study, approximately 20% of pa-
ients received 105% of the correct dosage of weight-
ased single-bolus tenecteplase administered prehospital;
his was associated with an approximately 2-fold rate of
ntracerebral hemorrhage versus lower doses among patients
eceiving unfractionated heparin as the concomitant anti-
hrombin agent (84). Mortality was also shown to be
ncreased in patients receiving an incorrect dosage of strep-
okinase or alteplase, which are dosed by intravenous infu-
ion based on body weight (85).
LEEDING COMPLICATIONS. Bleeding complications are
he main risks associated with fibrinolysis, although these
re usually only minor (e.g., puncture site bleeding after
CI). Major bleeding occurs in approximately 5% to 6% of
atients treated with fibrinolytics (75,76), and may be
educed by using more fibrin-specific agents and/or using
eparin more carefully. Although severe bleeding compli-
ations such as intracranial hemorrhage can be associated
ith high mortality, such serious complications occur in
pproximately 1% to 2% of patients treated with fibrinolytics
75,76), although more commonly in the elderly, who com-
rise a larger proportion of patients in general practice than in
linical trials.
mportance of Heparin Dosing
he ACC/AHA STEMI guidelines call for careful weight-
ased dosing of unfractionated heparin with fibrinolytic
herapy: The bolus should be 60 U/kg up to a maximum of
,000 U and initial infusion 12 U/kg/h up to a maximum
nitial dose of 1,000 U/h (2). A comparison of the
SSENT-2 and -3 trials showed that this careful dosing,
hen combined with down-titration of heparin as early as
h based on high activated partial thromboplastin times,
MI
ment of STEMI
lteplase Reteplase Tenecteplase
0 mg in 90 min
d on weight)*
10 U  2 (30 min apart),
each over 2 min
30–50 mg based on weight†
No Yes Yes
No No No
No No No
Mild Moderate Minimal
50 60 60
75 83 83
7 (100 mg dose) 0.8 0.9
  
  
3,404.78 2,872.50 2,917.48 for 50 mg
mg over the next 60 min to an overall maximum of 100 mg. †30 mg for weight 60 kg, 35 mgf STE
Treat
A
to 10
(base
0.4–0.
eed 35
k, 2005.
mbolysis In Myocardial Infarction.
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onfully weight-adjusted dosing (86).
acilitated PCI and Pharmacoinvasive Therapy
harmacoinvasive therapy is a strategy of planned PCI after
nitial pharmacologic reperfusion. In addition to potentially
educing time to initiation of treatment, an important
ationale for this strategy is that patients with TIMI flow
rade 2 to 3 before PCI achieve better clinical outcomes
87–90).
A number of recent studies have evaluated so-called
facilitated PCI,” where pharmacologic therapy is followed
mmediately by PCI, but at present the data suggest that it
s not beneficial and may be harmful. Worse outcomes were
een with facilitated PCI versus primary PCI in a recent
eta-analysis (91). However, that meta-analysis was largely
riven by the largest trial to date, the ASSENT-4 PCI trial,
hich showed that routine immediate PCI following full-
ose tenecteplase therapy was associated with higher rates of
brupt vessel closure, reinfarction, and death versus primary
CI alone in patients with only modest treatment delays
nd treated with low-dose heparin (92). One implication of
his trial is that patients receiving full-dose fibrinolytic
herapy who have signs of reperfusion should not undergo
outine immediate PCI, because there may be an early
rothrombotic state following fibrinolytic therapy that may
ncrease PCI risk.
Abciximab has been shown to modestly reduce mortality,
iven either prehospital, as seen in the ADMIRAL (Abcix-
mab Before Direct Angioplasty and Stenting in Myocardial
nfarction Regarding Acute and Long-Term Follow-Up)
tudy (93), or in general in the setting of primary PCI (but
ot with fibrinolysis), as shown in a meta-analysis (94).
The WEST (Which Early ST-Elevation Myocardial
nfarction Therapy) trial randomized 304 patients to fi-
rinolytic therapy at the earliest contact (prehospital or in
eferral hospital, with clopidogrel and enoxaparin), with or
ithout routine rescue or early invasive therapy, or to
rimary PCI (95). Tenecteplase and enoxaparin followed by
outine early invasive therapy had similar death and MI
ates to primary PCI. This supports the need for further
rials to assess the role of optimal early fibrinolytic therapy
including prehospital) and antithrombotic therapy versus
rimary PCI in settings where very rapid PCI is not
vailable.
Recently, the Leipzig Prehospital Fibrinolysis Group
ompared prehospital combination fibrinolysis with half-
ose reteplase (two 5-U boluses) plus intravenous abciximab
n conjunction with standard care and an alternative strategy
f prehospital combination fibrinolysis followed by facili-
ated PCI and found that the facilitated PCI strategy was
ssociated with significantly smaller infarct size and a
ignificantly higher rate of complete ST-segment resolution
96), supporting the need for further trials. Thus, the use of
djunctive glycoprotein IIb/IIIa inhibition may be impor- rant to the success of this approach. Additionally, a recent
ost-effectiveness study suggests that a facilitated PCI strat-
gy may have the potential for cost benefits in addition to
linical benefits for patients with STEMI being transferred
rom community hospitals to undergo PCI (97).
Although a facilitated PCI approach remains controver-
ial, and is presently regarded as a class IIb recommendation
n the ACC/AHA STEMI management guidelines (2),
hese data nonetheless suggest that there may be benefit in
elected instances where tertiary hospitals and community
ospitals can develop an integrated care delivery model. It is
oped that the FINESSE (Facilitated Intervention With
nhanced Reperfusion Speed to Stop Events) study, exam-
ning primary PCI with intravenous abciximab or facilitated
CI with abciximab alone or with reteplase, will further
nswer questions regarding the interaction between medical
nd interventional care in STEMI (98). In addition, future
tudies may determine the optimal time frame for PCI after
brinolysis; data suggest that delayed PCI may have benefits
ver immediate PCI after fibrinolysis (99).
Hub and Spoke” Network Model
nother potentially attractive approach to enhancing clini-
al outcomes in STEMI is the establishment of integrated
ystems of care between participating hospitals without
ardiac catheterization capability (spoke hospitals) and a
igh-volume tertiary center (hub hospital) whereby the early
anagement of STEMI can be systematically coordinated
y emergency medicine and cardiology personnel at all
articipating hospitals. The appeal of this approach is that it
eeks to make optimal use of existing personnel and re-
ources at hub and spoke hospitals without incurring addi-
ional institutional costs and recurring expenditures at those
poke hospitals that would require considerable additional
apital to mount and maintain a primary PCI program. In
uch a model, it is essential that both cardiologists and
mergency physicians at the hub and spoke hospitals com-
unicate closely and achieve, through consensus, a coordi-
ated management approach to expedite prompt early
harmacologic reperfusion at the spoke hospitals followed
y prompt triage and transport to the hub facility for
rimary PCI.
One such model has been developed in the Hartford,
onnecticut, area, comprising 5 spoke hospitals without
n-site catheterization or PCI capability in surrounding
ommunities and a single high-volume tertiary center with
ull 24/7 primary PCI capability. Over the past 6 years,
,560 consecutive STEMI patients have been followed
rospectively, of which 60% had their initial medical contact
t community hospitals. Among the first cohort of STEMI
atients in 2000 to 2003, 808 patients with acute STEMI
ithin 6 h of symptom onset were eligible for a pharmaco-
nvasive approach. The 30-day mortality was 1.6% among
atients who initially presented to community hospitals and
eceived bolus fibrinolytic and glycoprotein IIb/IIIa inhibi-
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he hub hospital and proceeded directly to primary PCI. By
ontrast, patients who presented initially to community
ospitals, did not receive antecedent fibrinolytic therapy
nd/or glycoprotein IIb/IIIa inhibitors, and were transfered
irectly to the hub hospital for primary PCI had a 30-day
ortality of 5.5% (100). In patients presenting initially to
ommunity hospitals, total ischemic time (time from first
edical contact at spoke hospital to first intracoronary
alloon inflation at hub hospital) was 241 min. These data
nderscore some of the logistical complexities and inevitable
ime delays encountered in patient transport from outlying
ommunity hospitals and highlight some of the benefits that
ight be achievable by combining early pharmacologic
eperfusion with expedited PCI using an integrated “hub
nd spoke” network approach.
Time to treatment for regional management of STEMI
atients who require transfer has been shown to be im-
roved by implementation at the Mayo Clinic in Rochester,
innesota, of a Fast Track protocol to minimize delays
101). Similarly, a standardized protocol and integrated
ystem of transfer for patients with STEMI requiring PCI
as been successfully implemented at 29 community hospi-
als in Minnesota, resulting in significant reductions in
oor-to-balloon times (44).
These examples demonstrate that it is feasible to imple-
ent procedures to minimize transfer-related time delays in
nitiating STEMI treatment. There is continuing interest in
harmacoinvasive strategies, which developed out of the
nacceptably long delays associated with transfer for PCI.
rials assessing different adjunctive pharmacologic regimens
re ongoing; in particular, there is interest in using a reduced
ose of fibrinolytics to attempt to minimize the risk of
ntracerebral and other bleeding complications, in combi-
ation with glycoprotein IIb/IIIa inhibitors to enhance
lot lysis and prevent additional platelet aggregation on
he clot (102).
onclusions
e-establishing prompt coronary blood flow and myocardial
issue perfusion as quickly as possible remains the most
mportant principle underlying early STEMI management.
rimary PCI and fibrinolysis are the 2 principal methods
roven to accomplish this and thus decrease mortality.
rimary PCI is a superior strategy when performed within
0 min of medical contact; however, this ACC/AHA
uality of care benchmark is very often not achieved.
atients who initially present to hospitals without PCI
apabilities remain one of the largest challenges to achieving
more widespread survival benefit with early reperfusion.
lthough primary PCI remains the “gold standard” of early
reatment for STEMI, the degree to which this can be
easibly expanded in the U.S. remains uncertain. Logistical,
nancial, and political issues abound, and it is unclear to
hat degree expanding PCI capability and access will leado improved clinical outcomes, especially given that low-
olume (or stand-alone) primary PCI centers may struggle
o achieve true 24/7 capability for prompt mechanical
eperfusion. In addition, expansion of PCI capability and
ccess alone may be offset by the costs of the transportation
ystem and keeping low-volume catheterization laboratories
pen during off-hours and the potential dangers of perform-
ng primary PCI by unskilled low-volume operators.
Beyond the window of opportunity of achieving door-to-
alloon times of 90 min, the advantage of PCI over
brinolysis is diminished. For STEMI patients who present
ithin 3 h of symptom onset, data showing superiority of
echanical versus pharmacologic reperfusion are less com-
elling, and more rapid treatment is even more important.
qually importantly, studies based on U.S. registries of
TEMI often show a substantial delay to treatment in
atients who undergo primary PCI, particularly in those
ho may not have access to qualified PCI facilities, require
ransfer for primary PCI, or who present for medical care
uring off-hours. These delays must be considered when a
eperfusion strategy is selected, because such patients may
chieve greater benefit with prompt fibrinolysis versus de-
ayed primary PCI.
Many groups are working on developing highly organized
etworks of EMS, ED, hospital administrations, and car-
iology to enhance the availability of rapid primary PCI, as
ell as the use of rapid fibrinolytic therapy when rapid PCI
s not available. To date, trials of fibrinolytic therapy
ollowed by immediate routine PCI show no benefit and
erhaps harm, although ongoing trials of facilitated PCI
ill provide additional information. The role for primary
CI for patients with modest delays beyond 90 min,
ompared with earliest fibrinolytic therapy with routine
escue PCI, is also being studied. In the meantime, the most
ompelling need is to work toward providing rapid reper-
usion therapy to all eligible patients with STEMI. For the
any patients who will not undergo primary PCI within
ptimal time frames, this may be most effectively achieved
y administration of fibrinolytics either prehospital or at a
poke hospital, followed by transfer to a hospital with PCI
acilities available at all times.
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